A New Job for Gilotrif
Boehringer Ingelheim's Gilotrif (afatinib) approved for squamous cell lung cancer
The US Food and Drug Administration has approved Gilotrif (afatinib) to treat squamous cell lung cancer.
Boehringer Ingelheim's Gilotrif is approved for those with advanced squamous cell lung cancer (SqCC) that has progressed despite treatment with platinum-based chemotherapy.
Gilotrif was already approved for those who have non-small cell lung cancer (NSCLC) with a certain type of epidermal growth factor receptor (EGFR) mutation.
Gilotrif's recent approval offers a new treatment option for a disease that is typically associated with a poor prognosis.
In a clinical trial, Gilotrif demonstrated a delay in the progression of lung cancer, an improvement in overall survival and an improvement in the control rate of lung cancer, according to a company-issued press release.
Common side effects reported with Gilotrif were diarrhea, rash or acne, mouth sores, decreased appetite and nausea.
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Health NewsNew Rx Stalls Advanced Lung Cancer
Gilotrif receives FDA approval for late stage non small cell lung cancer
Health NewsFDA Approves New Treatment for a Type of Late-Stage Lung Cancer
Gilotrif approved to treat patients with non small cell lung cancer
Prescription DrugsAdvancing Treatment of Advanced Lung Cancer
Advanced non small cell lung cancer has two new enemies